WO2013084150A1 - Novel crystal form of (2s)-2-amino-3-hydroxy-n-[2-methoxy-2-[(1z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide and method of preparation thereof - Google Patents

Novel crystal form of (2s)-2-amino-3-hydroxy-n-[2-methoxy-2-[(1z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide and method of preparation thereof Download PDF

Info

Publication number
WO2013084150A1
WO2013084150A1 PCT/IB2012/056953 IB2012056953W WO2013084150A1 WO 2013084150 A1 WO2013084150 A1 WO 2013084150A1 IB 2012056953 W IB2012056953 W IB 2012056953W WO 2013084150 A1 WO2013084150 A1 WO 2013084150A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
phenyl
methoxy
propanamide
Prior art date
Application number
PCT/IB2012/056953
Other languages
French (fr)
Inventor
Stéphane Mutti
Marc-Antoine Perrin
Joel Malpart
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of WO2013084150A1 publication Critical patent/WO2013084150A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates to a novel crystal form, hereinafter referred to as crystal Form ⁇ , of (2S)-2-amino-3-hydroxy-N-[2-memoxy-2-[(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl] phenyl]propanamide .
  • the invention also relates to processes for the preparation of said crystal Form I. pharmaceutical compositions and medicament comprising it, and its therapeutic use more particularly in the prevention and/or treatment, of cancers and/or tumors.
  • Cancer is a disease of humans and animals which is for the most part fatal and which is caused by the uncontrolled growth of endogenous cells. Cancer is the term for the formation of malignant tumors (malignomas) and of neoplasm (tumors or carcinomas) or for the malignant degeneration and disturbed maturation of white blood cells (leukemia, blood cancer).
  • the present invention relates more particularly to the anti-cancer compound named (2S)-2-ammo-3-hydroxy-N-[2-methoxy-2-[(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl] phenyl] propanamide or (Z)-N-[2-memoxy-5-[2-(3,4,5 rimethoxyphenyl)vinyl]phenyl]--L-serinamide, a well known combretastatin derivative known under the INN (International Non-proprietary Name) ombrabulin, which has the following structure of formula (A):
  • VDA vascular disrupting agent
  • R 1 , R 2 , R 3 and R 4 each independently represents a C 1 -3 alkyl group.
  • the present invention concerns the obtention of a new crystal form of ombrabulin, as its free base form.
  • crystal polymorphism is due to the ability of a compound to change its molecular conformation or to form different inter- and or intra-molecular interactions, particularly hydrogen bonds, which is reflected in different atom aiTangements in the crystal lattice of different polymorphs.
  • polymorphs of a compound can differ notably from each other by different energies in their crystal lattices and, therefore, generally have specific physical properties in the solid state such as crystal morphology, density, melting point, colour, chemical and physical stability, hygroscopy, solubility, dissolution rate, granular properties...
  • polymorphic forms of the same compound can exhibit different behaviors in terms of formulation, therapeutic activity and chemical and physical stability.
  • crystal Form I the compound of formula (A), as its free base form, can exist in a crystal form which is hereinafter referred to as crystal Form I.
  • the present invention provides a novel crystal form of (2S)-2-amino-3-hydroxy- N-[2-methoxy ⁇ 2-[(l Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide of formula (A)
  • crystal Form I of compound of formula (A) has at least one of the following characteristics:
  • Another aspects of the present invention are processes for the preparation of said crystal Form I of (2S)-2-amino-3-hydroxy-N-[2-methoxy-2-[(lZ)-2-(3,4,5- trimethoxyphenyl)ethenyl]phenyl] propanamide.
  • the present invention is directed to a particular process for preparing crystal Form I of (2S)-2-amino-3-hydroxy-N-[2-methoxy-2-[(lZ)-2-(3,4,5- trimethoxyphenyl)ethenyl]phenyl]propanamide comprising at least the step a) consisting to put in contact the hydrochloride salt of (2S)-2-amino-3-hydroxy-N-[2-methoxy-2-[(lZ)-2-(3,4,5- trimethoxyphenyl)ethenyl] phenyl]propanamide of formula (B):
  • Said compound of formula (B) can be prepared by conventional methods of organic synthesis practiced by those skilled in the art.
  • step a) is advantageously sodium hydroxide.
  • condition appropriate to promote the crystallization it is meant that the process according to the invention comprises:
  • step c By “partially distilling” in step c), it is meant a distillation of the isopropyl acetate so as to remove a part of the solvent (i.e. the removal of the solvent is not complete).
  • the distillation removes at least 20% of said solvent, more advantageously at least half of the solvent.
  • the step d) of cooling the medium below room temperature is advantageously carried out down to a temperature of about 5°C, advantageously down to 5°C ⁇ 5°C.
  • the step d) of cooling the medium below room temperature is advantageously followed by a step e) of maintaining the medium at the temperature achieved in the preceding step, for a duration of at least about 1 hour, advantageously for 1 to 2 hours.
  • the step d) of cooling the medium below room temperature may be preceded by a step d') of cooling the medium at about room temperature, advantageously at about 20°C, such as 20°C ⁇ 5°C.
  • the reaction medium is advantageously maintained at such a temperature for a few to several hours, such as about 12 hours.
  • the process according to the instant invention advantageously comprises a final step f) comprising the filtration, washing and drying of the crystal Form I of (2S)-2-amino-3-hydroxy-N-i2-methoxy-2-[(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] propanamide obtained as a result of the preceding steps.
  • the washing is advantageously earned out with isopropyl acetate.
  • a first variant consists in preparing and isolating the hydrochloride form of (2S)-2-amino-3-hydroxy-N-[2-methoxy-2-[(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] propanamide (compound (B)), and then carrying out the above-defined crystallization steps so as to obtain the compound (A), Form I;
  • a second variant is carried out without the prior isolation of the hydrochloride form of compound (A) (compound (B)), and consists in carrying out in situ the crystallization steps defined above, on a non-isolated intermediate (compound (B)) obtained starting from intermediate (Z)-(Ib) as defined below.
  • the process for preparing crystal Form I of (2S)'2-amino-3 ⁇ hydroxy-rl-[2-memoxy-2-[(lZ)-2-(3,4,5-trim.ethoxyphenyl)ethenyl]phenyl] propanamide may therefore comprise the preliminary step of synthesizing the hydrochloride salt of (2S)-2-ammo-3-hydroxy-N-[2-methoxy-2-[(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl] phenyl]propanamide, the crystallization step a) being carried out in situ by using a solvent like isopropyl acetate and applying the above defined steps to the so obtained hydrochloride derivative.
  • the processes according to the instant invention are particularly advantageous over the processes of preparation of ombrabulin base disclosed in the prior art since they do not comprise any purification steps by chromatography in order to recover the crystals of the compound of formula (A), and since they provide said compound of formula (A) Form I in good yields and with excellent chemical purity (higher than or equal to 99.5%).
  • the invention provides crystal Form 1 of (2S)-2-amino-3- hydroxy-N-[2-methoxy-2-[( lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] propanamide as defined herein substantially free of any other polymorph(s).
  • the ciystal Form I comprises less than 10%, preferably less than 2%, more preferably less than 0.5%, of any other polymorph(s) or impurity or impurities .
  • said crystal Form I of compound of formula (A) has an X-ray powder diffraction diagram substantially identical to that of Figure 1.
  • said crystal Form I of compound of formula (A) has an X-ray powder diffraction diagram substantially identical to that of Figure 1.
  • (A) has thermo-gravimetric analysis data substantially identical to that of Figure 2 in which no weight loss is observed from room temperature up to 170°C (i.e. up to a temperature far beyond 104°C which is the compound melting temperature).
  • said crystal Form I is an anhydrous compound.
  • said crystal Form I of compound of formula (A) has a water sorption/desorption 25°C isotherm substantially identical to that of Figure 3 in which no significant water uptake is observed. Said crystal form is thus not hygroscopic. Said crystal Form I is a stable anhydrous and non-hygroscopic crystal solid form. These characteristics are particularly advantageous for the processes of formulation, for the stability of said compound and thus for the conditions of storage.
  • said compound of formula (A) Form I according to the invention is useful for obtaining different addition salts of said compound with a pharmaceutically acceptable acid, for example the hydrochloride salt.
  • a pharmaceutically acceptable acid for example the hydrochloride salt.
  • Said compound of formula (A) Form I can advantageously be used directly to prepare formulation, by extemporaneous formation of an addition salt of said compound with a pharmaceutically acceptable acid,, for example hydrochloride salt, by addition of the corresponding acid, for example hydrochloric acid.
  • a pharmaceutically acceptable acid for example hydrochloride salt
  • the present invention also relates to said crystal Form I of (2S)-2-amino-3- hydroxy-N-[2 ⁇ methoxy ⁇ 2-[(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyi]phenyl]propanamide as a medicament.
  • the present invention provides, said crystal Form I of (2S)- 2-amino-3-hydroxy-N-[2-methoxy-2-[(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl] phenyl] propanamide for its use for preventing and/or treating cancers and/or tumors.
  • Another aspect of the present invention is the use of said crystal Form I of (2S)-2-amino-3-hydi xy-N-[2-methoxy-2-[(lZ)-2-(3,4,5-tnmethoxyphenyl)ethenyl] phenyl] propanamide for preventing and/or treating cancers and/or tumors.
  • Another aspect of the present invention is the use of said crystal Form I of (2S)-2-amino-3-hydroxy-N-[2-methoxy-2-[(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl] phenyl] propanamide for the manufacture of a medicament useful for preventing and/or treating cancers and/or tumors.
  • crystal Form I can advantageously be used directly as an Active Pharmaceutical Ingredient (API) to prepare formulations.
  • API Active Pharmaceutical Ingredient
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprises said compound of fonnula (A) Form I and also at least one pharmaceutically acceptable excipient.
  • compositions of the present compositions must be pharmaceutically acceptable.
  • a "pharmaceutically acceptable" component is one that is suitable for use with humans and/or other animals without undue adverse side effects (such as toxicity, irritation and allergic response) commensurate with a reasonable benefit/risk ratio.
  • the compositions of the present invention are generally administered to patients, which include, but are not limited to, mammals, for example, humans, by conventional routes known in the art.
  • the present invention further relates to the use of the pharmaceutical compositions of the invention for preventing and/ r treating cancer and/or tumors.
  • the cancer may be chosen among sarcoma, ovarian cancer and non-small cell lung cancer.
  • the tumor may be a solid tumor.
  • Figure 1 is an X-ray Powder Diffractogram of crystal Form I of (2S)-2-amino-3-hydroxy-N- [2-methoxy-2-[(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl] phenyl]propanamide of the present invention.
  • Figure 2 is Thenno-Gravimetric Analysis data of crystal Form I of (2S)-2-amino-3-hydroxy- N-[2-methoxy-2-[(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] propanamide of the present invention.
  • Figure 3 shows water sorption/desorption isotherms recorded at 25°C of ciystal Form I of (2S)-2-amino-3-hydroxy-N-[2-methoxy-2-[(l Z)-2-(3,4,5-trimethoxyphenyi)ethenyl] phenyl]propanamide of the present invention.
  • Example 1 Preparation of crystal Form I of (2S)-2-amino-3-hydroxy-N-[2-methoxy-2-[(lZ)- 2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide of formula (A) via the isolation of its hydrochloride form.
  • a solution of sodium hydroxide of 1 N (55.2 ml, 55.2 mmoles) is poured into a mixture comprising isopropyl acetate (400 ml), water (150 ml) and (2S)-2- amino-3-hydroxy-N-[2-methoxy-2-[(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] propanamide hydrochloride of formula (B) (20.0 g, 45.6 mmoles) so as to reach a pH equal to 12 in the aqueous phase.
  • the organic phase is collected, washed twice with 200 ml of water, and then partially concentrated. 200 ml of isopropyl acetate are then distilled at 35°C under 110 mbar. The resulting medium is cooled down to 20+5 °C and maintained at this temperature during 12 hours. The so obtained white suspension is then cooled down to 5+5°C during 1 to 2 hours before being filtered. The wet product on filter is washed twice with 20 ml of isopropyl acetate before being dried in vacuum (3.4.2 g, 77%) in order to obtain the product of formula (A). The so obtained product of formula (A) has a chemical purity higher than or equal to 99.5% as determined by High-Performance Liquid Chromatography (HPLC).
  • HPLC High-Performance Liquid Chromatography
  • Example 2 Preparation of crystal Form ⁇ of (2S)-2-amino-3-hydroxy-N-[2-methoxy-2-[(lZ)- 2-(3,4,5-tTiiBethoxyphenyl)ethenyl]phenyl]propanamide of formula (A) without the isolation of its hydrochloride form.
  • steps (i 7 ) to ( ⁇ ') are the same as the steps (i) to (iii) as described above in scheme 1 and thus are also described in WO 2009/1 18474.
  • TEA (32.0 ml, 0.230 mole) is poured into a medium comprising dichloromethane (DCM) (300 ml), compound (Z)-(Ib) (30 g, 0.085 mole) and compound of formula (IF) with Boc being the protective group (L-serine-N-BOC-acetonide ; 25.1 g, 0.102 mole) at 20°C.
  • DCM dichloromethane
  • Boc the protective group
  • L-serine-N-BOC-acetonide 25.1 g, 0.102 mole
  • T3P propanephosphonic acid anhydride
  • the medium is set and maintained at reflux during about 1 hour.
  • the reaction medium is then cooled down to 20-25°C and then water (300 ml) is added.
  • the organic phase is washed with a solution of sodium bicarbonate at 6% (300 ml, 0.213 mole). After decantation, the organic phase is washed again with water (300 ml). After partial concentration, methanolic hydrochloride (114 ml, 0.682 mole) and methanol (114 ml) are added. The reactive medium is stirred up for about 4-5 hours at 20-25°C. Water (180 ml) is added to the medium, and then phases are decanted. The organic phase is then further extracted with water (120 ml).
  • Aqueous phases are put together, and isopropyl acetate (390 ml, 13 volumes) and sodium hydroxide (69 ml, 0.690 mole) are added thereto.
  • the decanted organic phase is washed twice with 240 ml of water. Charcoal is added to the organic phase and stirred at 25°C during 1 hour, and then filtered.
  • the isopropyl acetate is partially distilled until 10 volumes under vacuum. The obtained slurry is cooled down to 5+5°C, maintained at this temperature during 1 hour, and then Filtered.
  • the wet product on filter is washed twice with 25 ml of isopropyl acetate before being dried under vacuum at 40°C (19.2 g, 56 %) in order to obtain the product of formula (A).
  • the so obtained product of formula (A) has a chemical purity higher than or equal to 99.5% as determined by HPLC.
  • Said crystal Form I according to the invention was characterized by several physical methods such as X-ray Powder Diffraction, Differential Scanning Calorimetry, Thenno-Gravimetric Analysis, Water- Activity isotherm measurement, as shown below.
  • Ka mean 1.54184A wavelength) running at 35 kV and 40 mA levels is used.
  • a Lynx-Eye detector completes the setup. Diagrams are recorded in the following conditions: a 1.5 to 40.0° scan in angle 2 ⁇ , 10 and 100 seconds counting time per degree in 2 ⁇ , according to the amount of powder to be analyzed, and ambient conditions of pressure, temperature and relative humidity.
  • the recording of a reference XRPD diagram of said Form I is carried out on a powder gently ground with agate mortar and pestle in order to reduce preferred orientation effects.
  • the so obtained reference XRPD diagram for a sample of Form I is shown in Figure 1.
  • the main peaks have 2-theta angles ( ⁇ 0.2 °) of 3.6, 7.1, 10.5, 11.2, 12.2 and 17.9 degrees 2-theta, more precisely of 3.6,. 7.1, 10.0, 10.5, 11.2, 12.2, 13.3, 14.3, 17.9, 18.7, 18.9 and 21.2 degrees 2-theta ( ⁇ 3 ⁇ 4 ct niean 1.54184A).
  • Analyses are carried out under a nitrogen stream with a PerkinElmer Pyris Diamond analyzer.
  • the calorimeter is also temperature-calibrated with indium and lead (onset temperatures of 429.8 K and 600.7 K respectively).
  • Energy calibration is done with a certified indium standard (melting enthalpy of 28.7 J/g).
  • a mechanical compressor (Intracooler II) is used to obtain and equilibrate the temperature program: from 290 to 465 K at a rate of 5 K/min under a constant nitrogen stream of 30 mL/min. Between 1.5 and 5 mg of the product to be analyzed is placed in a semi-open aluminum sample pan.
  • said Form I according to the invention exhibits a melting point (onset) around 104°C, advantageously 104°C ⁇ 2°C.
  • RH relative humidity
  • Form 1 is non-hygroscopic and physically stable over the entire range of relative humidity (0% to 90% RH).

Abstract

The present invention relates to a crystal form of (2S)-2-amino-3-hydroxy-N-[2-methoxy-2- [(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide of formula A (A) which is designated as Form I.

Description

NOVEL CRYSTAL FORM OF (2S)-2-AMINO-3-HYDROXY-N-[2-METHOXY-2-[(lZ 2- (3,4,5-TRIMETHOXYPHENYL)£THENYL]PHENYL]PROPANAMIDE AND METHOD
OF PREPARATION THEREOF
The present invention relates to a novel crystal form, hereinafter referred to as crystal Form Ϊ, of (2S)-2-amino-3-hydroxy-N-[2-memoxy-2-[(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl] phenyl]propanamide .
The invention also relates to processes for the preparation of said crystal Form I. pharmaceutical compositions and medicament comprising it, and its therapeutic use more particularly in the prevention and/or treatment, of cancers and/or tumors.
Cancer is a disease of humans and animals which is for the most part fatal and which is caused by the uncontrolled growth of endogenous cells. Cancer is the term for the formation of malignant tumors (malignomas) and of neoplasm (tumors or carcinomas) or for the malignant degeneration and disturbed maturation of white blood cells (leukemia, blood cancer).
For obvious reasons, there is a permanent need to identify new drugs for preventing and/or treating cancers and/or to increase the efficacy of existing anti-cancer drugs.
The present invention relates more particularly to the anti-cancer compound named (2S)-2-ammo-3-hydroxy-N-[2-methoxy-2-[(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl] phenyl] propanamide or (Z)-N-[2-memoxy-5-[2-(3,4,5 rimethoxyphenyl)vinyl]phenyl]--L-serinamide, a well known combretastatin derivative known under the INN (International Non-proprietary Name) ombrabulin, which has the following structure of formula (A):
Figure imgf000002_0001
Said compound is particularly known as a vascular disrupting agent (VDA) of tumors. Some stilbene compounds of formula (I):
Figure imgf000003_0001
wherein X represents a hydrogen atom or a nitrile group and Y is an amino acid acyl group, as well as a process for their preparation have already been disclosed in EP 733 085, by Monk et al. ("Design, Synthesis, and biological evaluation of combretastatin nitrogen-containing derivatives as inhibitors of tubulin assembly and vascular disrupting agents", Bioorganic & Medicinal Chemistry 1.4 (2006) 3231-3244), in the patent US 6,759,555 and in the patent applications WO2011/067538 and WO2009/118474.
Further, US 6,930,205 and US 5,731,353 disclose a process for preparing aminostilbene derivatives of formula (2) :
Figure imgf000003_0002
wherein R1, R2, R3 and R4 each independently represents a C1-3 alkyl group.
US 6,784,315 describes a stilbene derivative type IV crystal form of formula (A) as above, however in its hydrochloride form„as well as a process for its preparation.
Finally, (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyI]-L-serinamide, also known as AVE8062 or ombrabulin, is described in EP 731 085 and can be prepared according to the process disclosed in WO 03/084919.
However, none of the prior art documents describes crystallization step of ombrabulin in the form of its free base. US 5,674,906 merely describes a process which comprises a step of purification through silica-gel column chromatography and Monk et al. disclose a process which comprises a step of purification by thin layer chromatography (TLC). Importantly, neither US 5,674,906, nor Monk et al. describe in which physical form ombrabulin base may obtained, let alone whether a crystalline form may exist.
Hence, the present invention concerns the obtention of a new crystal form of ombrabulin, as its free base form.
Indeed, it is known that the identification of new crystal forms of active ingredient useful for preventing and/or treating cancers and /or tumors may be particularly interesting.
It is also known that the ability of a substance to exist in mo e tiiitn one crystal form is defined as crystal polymorphism and its different crystal forms are called polymorphs.
In general, crystal polymorphism is due to the ability of a compound to change its molecular conformation or to form different inter- and or intra-molecular interactions, particularly hydrogen bonds, which is reflected in different atom aiTangements in the crystal lattice of different polymorphs. Thus, polymorphs of a compound can differ notably from each other by different energies in their crystal lattices and, therefore, generally have specific physical properties in the solid state such as crystal morphology, density, melting point, colour, chemical and physical stability, hygroscopy, solubility, dissolution rate, granular properties...
In other words, polymorphic forms of the same compound can exhibit different behaviors in terms of formulation, therapeutic activity and chemical and physical stability.
Unexpectedly, the inventors have discovered that the compound of formula (A), as its free base form, can exist in a crystal form which is hereinafter referred to as crystal Form I.
Thus, the present invention provides a novel crystal form of (2S)-2-amino-3-hydroxy- N-[2-methoxy~2-[(l Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide of formula (A)
Figure imgf000004_0001
(A) which is designated as Form I.
More particularly, said crystal Form I of compound of formula (A) has at least one of the following characteristics:
(a) an X-ray (λθι) powder diffraction pattern with peaks at about 3.6, 7.1, 10.5, 11.2, 12.2 and- 17.9 ±0.2 degrees 2-theta,
(b) a melting point (onset) around 104°C.
PREPARATION OF CRYSTAL FORM I
Another aspects of the present invention are processes for the preparation of said crystal Form I of (2S)-2-amino-3-hydroxy-N-[2-methoxy-2-[(lZ)-2-(3,4,5- trimethoxyphenyl)ethenyl]phenyl] propanamide.
Thus, the present invention is directed to a particular process for preparing crystal Form I of (2S)-2-amino-3-hydroxy-N-[2-methoxy-2-[(lZ)-2-(3,4,5- trimethoxyphenyl)ethenyl]phenyl]propanamide comprising at least the step a) consisting to put in contact the hydrochloride salt of (2S)-2-amino-3-hydroxy-N-[2-methoxy-2-[(lZ)-2-(3,4,5- trimethoxyphenyl)ethenyl] phenyl]propanamide of formula (B):
Figure imgf000005_0001
with a solvent like isopropyl acetate and in the presence of a base, in conditions appropriate to promote the crystallization of said (2S)-2-amino-3-hydroxy-N-[2-methoxy-2-[(lZ)-2-(3.4,5- trimethoxyphenyl)ethenyl]phenyi] propanamide crystal Form 1.
Said compound of formula (B) can be prepared by conventional methods of organic synthesis practiced by those skilled in the art.
For example, the steps to obtain said compound (B) in which the starting materials are nitromethoxybenzaldehyde and trimethoxybenzylphosphonium bromide (or chloride) are described in WO 2009/118474.
The above-mentioned base (step a)) is advantageously sodium hydroxide. By "conditions appropriate to promote the crystallization" as defined above, it is meant that the process according to the invention comprises:
b) a step of collecting the organic phase,
c) a step of partially distilling the isopropyl acetate,
d) a step of cooling the resulting medium below room temperature.
By "partially distilling" in step c), it is meant a distillation of the isopropyl acetate so as to remove a part of the solvent (i.e. the removal of the solvent is not complete). Advantageously, the distillation removes at least 20% of said solvent, more advantageously at least half of the solvent.
The step d) of cooling the medium below room temperature is advantageously carried out down to a temperature of about 5°C, advantageously down to 5°C ± 5°C.
The step d) of cooling the medium below room temperature is advantageously followed by a step e) of maintaining the medium at the temperature achieved in the preceding step, for a duration of at least about 1 hour, advantageously for 1 to 2 hours.
The step d) of cooling the medium below room temperature may be preceded by a step d') of cooling the medium at about room temperature, advantageously at about 20°C, such as 20°C ± 5°C. The reaction medium is advantageously maintained at such a temperature for a few to several hours, such as about 12 hours.
The process according to the instant invention advantageously comprises a final step f) comprising the filtration, washing and drying of the crystal Form I of (2S)-2-amino-3-hydroxy-N-i2-methoxy-2-[(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] propanamide obtained as a result of the preceding steps. The washing is advantageously earned out with isopropyl acetate.
The process according to the invention can be carried out in two variants:
a first variant consists in preparing and isolating the hydrochloride form of (2S)-2-amino-3-hydroxy-N-[2-methoxy-2-[(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] propanamide (compound (B)), and then carrying out the above-defined crystallization steps so as to obtain the compound (A), Form I;
a second variant is carried out without the prior isolation of the hydrochloride form of compound (A) (compound (B)), and consists in carrying out in situ the crystallization steps defined above, on a non-isolated intermediate (compound (B)) obtained starting from intermediate (Z)-(Ib) as defined below.
In a specific embodiment, the process for preparing crystal Form I of (2S)'2-amino-3~hydroxy-rl-[2-memoxy-2-[(lZ)-2-(3,4,5-trim.ethoxyphenyl)ethenyl]phenyl] propanamide may therefore comprise the preliminary step of synthesizing the hydrochloride salt of (2S)-2-ammo-3-hydroxy-N-[2-methoxy-2-[(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl] phenyl]propanamide, the crystallization step a) being carried out in situ by using a solvent like isopropyl acetate and applying the above defined steps to the so obtained hydrochloride derivative.
As known in the Art, the synthesis of said hydrochloride derivative of (2S)-2-amino-3-hydroxy-N-[2-methoxy-2-[(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] propanamide may be carried out starting from the protected intermediate (Z)-(Ib), wherein PG represents a protecting group such as boc (tert-butoxycarbonyl):
Figure imgf000007_0001
The processes according to the instant invention are particularly advantageous over the processes of preparation of ombrabulin base disclosed in the prior art since they do not comprise any purification steps by chromatography in order to recover the crystals of the compound of formula (A), and since they provide said compound of formula (A) Form I in good yields and with excellent chemical purity (higher than or equal to 99.5%).
By "good yields" in the present invention, it is meant that said compound of formula (A). Form I, is obtained with a yield higher than or equal to 56% starting from the protected intermediate (Z)-(Ib), advantageously higher than or equal to 77% starting from the compound of formula (B). CRYSTAL FORM I ACCORDING TO THE INVENTION
In a preferred aspect, the invention provides crystal Form 1 of (2S)-2-amino-3- hydroxy-N-[2-methoxy-2-[( lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] propanamide as defined herein substantially free of any other polymorph(s).
In a further preferred aspect, the crystal Form I of (2S)-2-amino-3-hydroxy-N-
[2-methoxy-2-[(lZ)-2-(3,4,5-trime1h.oxyphenyl)ethenyl]phenyl]pi panamide as herein defined is substantially free of impurities.
By "substantially free", it is meant that the ciystal Form I comprises less than 10%, preferably less than 2%, more preferably less than 0.5%, of any other polymorph(s) or impurity or impurities .
In another preferred embodiment, said crystal Form I of compound of formula (A) has an X-ray powder diffraction diagram substantially identical to that of Figure 1. In another preferred embodiment, said crystal Form I of compound of formula
(A) has thermo-gravimetric analysis data substantially identical to that of Figure 2 in which no weight loss is observed from room temperature up to 170°C (i.e. up to a temperature far beyond 104°C which is the compound melting temperature). Thus said crystal Form I is an anhydrous compound.
In another preferred embodiment, said crystal Form I of compound of formula (A) has a water sorption/desorption 25°C isotherm substantially identical to that of Figure 3 in which no significant water uptake is observed. Said crystal form is thus not hygroscopic. Said crystal Form I is a stable anhydrous and non-hygroscopic crystal solid form. These characteristics are particularly advantageous for the processes of formulation, for the stability of said compound and thus for the conditions of storage.
The instrumentation and method are described in the Experimental part below.
In a further aspect, said compound of formula (A) Form I according to the invention is useful for obtaining different addition salts of said compound with a pharmaceutically acceptable acid, for example the hydrochloride salt. Using the compound of formula (A) Form I according to the invention as an intermediate for obtaining different addition salts provides the advantages of a synthesis route devoid of purification steps by chromatography, and of using an intermediate in base form with excellent purity and optimal storage conditions (stability, non-hygroscopicity).
Said compound of formula (A) Form I can advantageously be used directly to prepare formulation, by extemporaneous formation of an addition salt of said compound with a pharmaceutically acceptable acid,, for example hydrochloride salt, by addition of the corresponding acid, for example hydrochloric acid.
APPLICATIONS
The present invention also relates to said crystal Form I of (2S)-2-amino-3- hydroxy-N-[2~methoxy~2-[(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyi]phenyl]propanamide as a medicament.
In a further aspect, the present invention provides, said crystal Form I of (2S)- 2-amino-3-hydroxy-N-[2-methoxy-2-[(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl] phenyl] propanamide for its use for preventing and/or treating cancers and/or tumors.
Another aspect of the present invention is the use of said crystal Form I of (2S)-2-amino-3-hydi xy-N-[2-methoxy-2-[(lZ)-2-(3,4,5-tnmethoxyphenyl)ethenyl] phenyl] propanamide for preventing and/or treating cancers and/or tumors.
Another aspect of the present invention is the use of said crystal Form I of (2S)-2-amino-3-hydroxy-N-[2-methoxy-2-[(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl] phenyl] propanamide for the manufacture of a medicament useful for preventing and/or treating cancers and/or tumors.
Said, crystal Form I can advantageously be used directly as an Active Pharmaceutical Ingredient (API) to prepare formulations.
Thus, the present invention also relates to a pharmaceutical composition comprises said compound of fonnula (A) Form I and also at least one pharmaceutically acceptable excipient.
All components of the present compositions must be pharmaceutically acceptable. As used herein, a "pharmaceutically acceptable" component is one that is suitable for use with humans and/or other animals without undue adverse side effects (such as toxicity, irritation and allergic response) commensurate with a reasonable benefit/risk ratio. The compositions of the present invention are generally administered to patients, which include, but are not limited to, mammals, for example, humans, by conventional routes known in the art.
The present invention further relates to the use of the pharmaceutical compositions of the invention for preventing and/ r treating cancer and/or tumors.
For example, the cancer may be chosen among sarcoma, ovarian cancer and non-small cell lung cancer. The tumor may be a solid tumor.
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is an X-ray Powder Diffractogram of crystal Form I of (2S)-2-amino-3-hydroxy-N- [2-methoxy-2-[(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl] phenyl]propanamide of the present invention.
Figure 2 is Thenno-Gravimetric Analysis data of crystal Form I of (2S)-2-amino-3-hydroxy- N-[2-methoxy-2-[(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] propanamide of the present invention.
Figure 3 shows water sorption/desorption isotherms recorded at 25°C of ciystal Form I of (2S)-2-amino-3-hydroxy-N-[2-methoxy-2-[(l Z)-2-(3,4,5-trimethoxyphenyi)ethenyl] phenyl]propanamide of the present invention. EXAMPLES
Example 1: Preparation of crystal Form I of (2S)-2-amino-3-hydroxy-N-[2-methoxy-2-[(lZ)- 2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide of formula (A) via the isolation of its hydrochloride form.
This synthesis can be illustrated by scheme 1 as shown below:
Figure imgf000011_0001
Scheme 1
The steps (i) to (iv) as described in Scheme 1 have already been described in WO 2009/118474.
Step (ίν'):
At a temperature of 10-20°C, a solution of sodium hydroxide of 1 N (55.2 ml, 55.2 mmoles) is poured into a mixture comprising isopropyl acetate (400 ml), water (150 ml) and (2S)-2- amino-3-hydroxy-N-[2-methoxy-2-[(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] propanamide hydrochloride of formula (B) (20.0 g, 45.6 mmoles) so as to reach a pH equal to 12 in the aqueous phase.
The organic phase is collected, washed twice with 200 ml of water, and then partially concentrated. 200 ml of isopropyl acetate are then distilled at 35°C under 110 mbar. The resulting medium is cooled down to 20+5 °C and maintained at this temperature during 12 hours. The so obtained white suspension is then cooled down to 5+5°C during 1 to 2 hours before being filtered. The wet product on filter is washed twice with 20 ml of isopropyl acetate before being dried in vacuum (3.4.2 g, 77%) in order to obtain the product of formula (A). The so obtained product of formula (A) has a chemical purity higher than or equal to 99.5% as determined by High-Performance Liquid Chromatography (HPLC). Example 2: Preparation of crystal Form ί of (2S)-2-amino-3-hydroxy-N-[2-methoxy-2-[(lZ)- 2-(3,4,5-tTiiBethoxyphenyl)ethenyl]phenyl]propanamide of formula (A) without the isolation of its hydrochloride form.
This synthesis can be illustrated by scheme 2 as shown below:
Figure imgf000012_0001
The steps (i7) to (ϊϋ') are the same as the steps (i) to (iii) as described above in scheme 1 and thus are also described in WO 2009/1 18474.
Step(iv'):
TEA (32.0 ml, 0.230 mole) is poured into a medium comprising dichloromethane (DCM) (300 ml), compound (Z)-(Ib) (30 g, 0.085 mole) and compound of formula (IF) with Boc being the protective group (L-serine-N-BOC-acetonide ; 25.1 g, 0.102 mole) at 20°C. Then, a solution of propanephosphonic acid anhydride (T3P) in the DCM (92.4 g, 0.145 mole) is added to the reaction medium. The medium is set and maintained at reflux during about 1 hour. The reaction medium is then cooled down to 20-25°C and then water (300 ml) is added. After decantation, the organic phase is washed with a solution of sodium bicarbonate at 6% (300 ml, 0.213 mole). After decantation, the organic phase is washed again with water (300 ml). After partial concentration, methanolic hydrochloride (114 ml, 0.682 mole) and methanol (114 ml) are added. The reactive medium is stirred up for about 4-5 hours at 20-25°C. Water (180 ml) is added to the medium, and then phases are decanted. The organic phase is then further extracted with water (120 ml). Aqueous phases are put together, and isopropyl acetate (390 ml, 13 volumes) and sodium hydroxide (69 ml, 0.690 mole) are added thereto. The decanted organic phase is washed twice with 240 ml of water. Charcoal is added to the organic phase and stirred at 25°C during 1 hour, and then filtered. The isopropyl acetate is partially distilled until 10 volumes under vacuum. The obtained slurry is cooled down to 5+5°C, maintained at this temperature during 1 hour, and then Filtered. The wet product on filter is washed twice with 25 ml of isopropyl acetate before being dried under vacuum at 40°C (19.2 g, 56 %) in order to obtain the product of formula (A). The so obtained product of formula (A) has a chemical purity higher than or equal to 99.5% as determined by HPLC.
' EXPERIMENT ALS
Said crystal Form I according to the invention (samples obtained according to the process of scheme 1) was characterized by several physical methods such as X-ray Powder Diffraction, Differential Scanning Calorimetry, Thenno-Gravimetric Analysis, Water- Activity isotherm measurement, as shown below.
X-Rav Powder Diffraction (XRPD)
XRPD experiments are carried out on a Braker AXS D8 powder diffractometer using the Bragg-Brentano parafocusing geometry. A thin layer of the product is deposited on a single-crystal silicon wafer, cut out according to Si (510) crystallographic orientation that, by systematic extinction, impedes any Bragg reflection. A sealed copper anode X-ray tube (kcu
Kamean 1.54184A wavelength) running at 35 kV and 40 mA levels is used. A Lynx-Eye detector completes the setup. Diagrams are recorded in the following conditions: a 1.5 to 40.0° scan in angle 2Θ, 10 and 100 seconds counting time per degree in 2Θ, according to the amount of powder to be analyzed, and ambient conditions of pressure, temperature and relative humidity. The recording of a reference XRPD diagram of said Form I is carried out on a powder gently ground with agate mortar and pestle in order to reduce preferred orientation effects. The so obtained reference XRPD diagram for a sample of Form I is shown in Figure 1.
According to Figure 1, the main peaks have 2-theta angles (± 0.2 °) of 3.6, 7.1, 10.5, 11.2, 12.2 and 17.9 degrees 2-theta, more precisely of 3.6,. 7.1, 10.0, 10.5, 11.2, 12.2, 13.3, 14.3, 17.9, 18.7, 18.9 and 21.2 degrees 2-theta (λ<¾ ctniean 1.54184A).
Differential Scanning Calorimetrv (DSC)
Analyses are carried out under a nitrogen stream with a PerkinElmer Pyris Diamond analyzer. The calorimeter is also temperature-calibrated with indium and lead (onset temperatures of 429.8 K and 600.7 K respectively). Energy calibration is done with a certified indium standard (melting enthalpy of 28.7 J/g). A mechanical compressor (Intracooler II) is used to obtain and equilibrate the temperature program: from 290 to 465 K at a rate of 5 K/min under a constant nitrogen stream of 30 mL/min. Between 1.5 and 5 mg of the product to be analyzed is placed in a semi-open aluminum sample pan.
An endo thermic peak is recorded (onset around 104°C). This phenomenon corresponds to the melting of the sample.
Hence, said Form I according to the invention exhibits a melting point (onset) around 104°C, advantageously 104°C ± 2°C.
Thermo-Gravimctrie Analysis (TGA)
Analyses are carried out using a TG209C Netzsch Instrument. A sample mass of 5 to 10 mg is deposited in an aluminium crucible. The TGA analysis is conducted under a dry nitrogen stream at 10 mL/min. The sample is heated from 25 to 270 °C at a rate of 5°C/min. Figure 2 shows thermo-gravimetric analysis data of said Form I. No weight loss is observed from room temperature up to 170°C (i.e. up to a temperature far beyond 104°C which is the compound melting temperature). Thus said crystal Form I is an anhydrous compound. Water- Activity isotherm (DVS)
All experiments are performed on a DVS-1 automated gravimetric vapor sorption analyser (Surface Measurement Systems Ltd., London, UK). The DVS-1 measures the uptake and loss of vapor gravimetrically using a Cahn D200 recording ultra-microbalance with a mass resolution of ±0.1 μg. A controlled relative humidity is generated by mixing different proportions of dry and water saturated carrier gas streams (monitored by mass flow conti llers). The temperature is maintained constant, ± 0.1 °C, by enclosing the entire system in a temperature-controlled incubator.
A sample size between 4 and 10 mg is used. Prior to being exposed to any water vapor the samples were dried at 0% relative humidity (RH) to remove any surface water present and establish a dry, baseline mass. Next, the samples are exposed to an increasing relative humidity raised by a step of 5% RH from 0% to 90% RH. At each stage, the sample mass is allowed to reach equilibrium before the relative humidity is increased or decreased (considering that equilibrium is established when dm/dt ratio (m = mass ; t = time) does not exceed the value of 3.3 10"4 mg/s during 30 minutes). If equilibrium state is not reached, the change in relative humidity takes place automatically after 600 minutes.
From the complete moisture sorption and desorption profile an isotherm is calculated using the DVS Advanced Analysis Suite v3.6. All experiments are performed at 25°C. Figure 3 shows water sorption/desorption isotherm recorded at 25°C.
At 90% RH a total water uptake of less than 0.15% (w/w) is observed.
A slight and usual hysteresis between the sorption and desorption steps is observed from 50% to 80% RH.
In addition after DVS experiment no solid phase change was observed as confirmed by XRPD.
Thus at 25°C said Form 1 is non-hygroscopic and physically stable over the entire range of relative humidity (0% to 90% RH).

Claims

1. Crystal form of (2S)-2-amino-3-hydroxy-N-[2-methoxy-2-[(lZ)-2-(3}4,5- trimethoxyphenyl)ethenyl]phenyl]propanamide of formula (A):
Figure imgf000016_0001
which is designated as Form I.
2. Crystal form of compound of formula (A) according to claim 1 , having at least one of the following characteristics:
(a) an X-ray ( Cu) powder diffraction pattern with peaks at about 3.6, 7.1, 10.5, 1 1.2, 12.2 and 17.9 ±0.2 degrees 2-theta,
(b) a melting point (onset) around 104°C.
3. Medicament, characterized in that it comprises a compound of formula (A) according to any one of claims 1 to 2.
4. Pharmaceutical composition, characterized in that it comprises a compound of formula (A) according to any one of claims 1 to 2, and also at least one pharmaceutically acceptable excipient.
5. Compound of formula (A) according to any one of claims 1 to 2 for use as a medicament.
6. Compound of formula (A) according to any one of claims 1 to 2 for use in the prevention and/or treatment of cancers and/or tumors.
7. Compound of formula (A) for use according to the preceding claim wherein the cancer is chosen among sarcoma, ovarian cancer and non-small cell lung cancer.
8. Compound of formula (A) for use according to the preceding claim wherein the tumor is a solid tumor.
9. Process for the preparation of (2S)-2-amino-3-hydroxy-N-[2-methoxy-
2-[(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide Form I according to claims 1 to 2 comprising at least the step a) consisting to put in contact the hydrochloride salt of (2S)-2-amino-3-hydroxy-N-[2-methoxy-2- ( 1 Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]phenyl] propanamide of fonnula (B):
Figure imgf000017_0001
with, a solvent like isopropyl acetate and in the presence of a base, in conditions appropriate to promote the crystallization of said (2S)-2-amino-3-hydroxy- -[2-methoxy-2- [(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] propanamide Form I.
10. Process according to the preceding claim comprising the preliminary step of synthetizing the hydrochloride salt of (2S)-2-amino-3-hydroxy-N-[2-methoxy-2- [(lZ)-2-(3,4,5-trimethoxyphenyl)ethenyl] phenyl]propanamide, the crystallization step a) being carried out in situ by using said solvent.
11. Process according to claim 9 or 10, which comprises the following steps: a) putting into contact contact the hydrochloride salt of (2S)-2-amino-
3-hydroxy- -[2-methoxy-2-[(lZ)-2-(3,4,5-trimethoxyphenyl) ethenyl]phenyl] propanamide of formula (B) defined in claim 9 with and in the presence of a base,
b) collecting the organic phase,
c) partially distilling the isopropyl acetate,
d) cooling the resulting medium below room temperature.
12. Process according to any of claims 9 to 11, wherein the base is sodium hydroxide.
13. Process according to claim 11 or 12, wherein the medium is cooled to 5°C ±
5°C in step d).
14. Use of a compound according to any one of claims 1 to 2 for preparing an addition salt of said compound with a pharmaceutically acceptable acid.
15. Use of a compound accordmg to claim 14, where the addition salt is hydrochloride salt.
16. Use of a compound according to any one of claims 1 to 2 for preparing a formulation by extemporaneous formation of an addition salt of said compound with a pharmaceutically acceptable acid, by addition of the corresponding acid. hydrochloride salt.
PCT/IB2012/056953 2011-12-06 2012-12-04 Novel crystal form of (2s)-2-amino-3-hydroxy-n-[2-methoxy-2-[(1z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide and method of preparation thereof WO2013084150A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11192178.9 2011-12-06
EP11192178 2011-12-06

Publications (1)

Publication Number Publication Date
WO2013084150A1 true WO2013084150A1 (en) 2013-06-13

Family

ID=47522760

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/056953 WO2013084150A1 (en) 2011-12-06 2012-12-04 Novel crystal form of (2s)-2-amino-3-hydroxy-n-[2-methoxy-2-[(1z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide and method of preparation thereof

Country Status (1)

Country Link
WO (1) WO2013084150A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014108066A1 (en) * 2013-01-11 2014-07-17 浙江大德药业集团有限公司 Synthesis of amino-combretastatin derivatives and use as oral anti-tumour drugs
EP2805705A1 (en) 2013-05-23 2014-11-26 IP Gesellschaft für Management mbH Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674906A (en) * 1995-03-07 1997-10-07 Ajinomoto Co., Inc. Stilbene compounds and pharmaceutical compositions containing them
EP1264821A1 (en) * 2000-03-17 2002-12-11 Ajinomoto Co., Inc. Novel crystal of stilbene derivative and process for producing the same
US20110124899A1 (en) * 2008-02-28 2011-05-26 Sanofi-Aventis Method for preparing combretastatin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674906A (en) * 1995-03-07 1997-10-07 Ajinomoto Co., Inc. Stilbene compounds and pharmaceutical compositions containing them
EP1264821A1 (en) * 2000-03-17 2002-12-11 Ajinomoto Co., Inc. Novel crystal of stilbene derivative and process for producing the same
US20110124899A1 (en) * 2008-02-28 2011-05-26 Sanofi-Aventis Method for preparing combretastatin

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014108066A1 (en) * 2013-01-11 2014-07-17 浙江大德药业集团有限公司 Synthesis of amino-combretastatin derivatives and use as oral anti-tumour drugs
EP2805705A1 (en) 2013-05-23 2014-11-26 IP Gesellschaft für Management mbH Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide

Similar Documents

Publication Publication Date Title
EP2280955B1 (en) Crystalline form of 6-ý(4s)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl¨pyridazin-3-amine
EP3201197B1 (en) Acid addition salt of ibrutinib
EA025438B1 (en) CRYSTALLINE COMPLEX OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(β-D-GLUCOPYRANOS-1-YL)BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTSCRYSTALLINE COMPLEX OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(β-D-GLUCOPYRANOS-1-YL)BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
US9221815B2 (en) Solid state form of vemurafenib choline salt
WO2012051246A1 (en) Tapentadol hydrobromide and crystalline forms thereof
TW201736343A (en) Novel crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine salt
KR20110110293A (en) Novel forms of bendamustine free base
CA2900951A1 (en) Solid state forms of vemurafenib hydrochloride
KR20100022081A (en) Crystalline rotigotine base and preparation process therefor
KR102552795B1 (en) crystalline form
WO2013084150A1 (en) Novel crystal form of (2s)-2-amino-3-hydroxy-n-[2-methoxy-2-[(1z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide and method of preparation thereof
JP2014533719A (en) Aprepitant L-proline solvate-composition and co-crystal
US8865897B2 (en) Crystal modifications-3-(1H-indol-3-yl)-4- [4-methyl-piperazin-1-yl)-quinazolin-4-yl] -pyrrole-2, 5-D ione
US20150366864A1 (en) Crystalline form of 6-[(4s)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2019056003A1 (en) Co-crystals of neflamapimod (vx-745)
TW201329024A (en) Novel crystal form of (2S)-2-amino-3-hydroxy-N-[2-methoxy-2-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide and method of preparation thereof
CN109843880B (en) Crystalline forms of 4- (2- ((1R, 2R) -2-hydroxycyclohexylamino) benzothiazol-6-yloxy) -N-methylpyridine amide
KR102013566B1 (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
US8598201B2 (en) Polymorphs of 6-(piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride
JP5600597B2 (en) Compounds and methods for treating cancer
US9533953B2 (en) Method of preparation of crystal forms of 4-(cyclopropylmethoxy)-n-(3,5-dichloro-1-oxidopyridyn-4-yl)-5-methoxypyridine-2-carboxamide and crystal forms thereof
CA2933371A1 (en) Polymorphic forms of a steroid-like compound and methods for the preparation and use thereof
KR20230143165A (en) Benzazepine compounds, methods for their preparation and pharmaceutical uses thereof
WO2009118758A2 (en) Novel crystalline forms of desvenlafaxine succinate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12813128

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12813128

Country of ref document: EP

Kind code of ref document: A1